Question explored with the scientific record
Conversation so far
- 1 Amoxcillin + Clavunic acid
- 2 How do guidelines recommend treating acute bacterial sinusitis?
Answered on this page ↓
How do guidelines recommend treating acute bacterial sinusitis?
The short version: guidelines recommend antibiotics only for confirmed bacterial cases, and the evidence for which antibiotic is best is thin and conflicted.
The most recent US guideline in the retrieved records, from the CDC in 2001, says most acute rhinosinusitis is viral and only about 0.2% to 2% of viral colds turn bacterial [8]. It recommends antibiotics only when symptoms last 7 days or more with maxillary pain and purulent discharge [8]. For those patients, it recommends the narrowest-spectrum agent, typically amoxicillin [8].
A 2000 evidence report from the Agency for Health Care Policy and Research found that newer antibiotics were not significantly better than amoxicillin, with a relative risk of clinical failure of 0.85 (0.62-1.17) [5]. The same report found that antibiotics overall beat placebo, but the absolute benefit was modest: about 47% cured versus 32% [5]. That means about 7 people need antibiotics for one to benefit.
The retrieved studies on specific drugs all have serious limitations. The 2018 trial of inhaled thiamphenicol versus oral amoxicillin/clavulanate was open-label with only 30 patients per group [1]. The 2020 Polydexa study compared two different nasal sprays on top of the same antibiotic, not the antibiotic alone [2]. The 2026 CO2-enriched spray study had only 54 patients and a sex imbalance between groups [3]. The roxithromycin review was a narrative review, not a trial [4]. The amoxicillin/clavulanate trials from 2006 were nonrandomized and funded by the manufacturer [6, 7].
The evidence does not support one antibiotic over another for routine cases. The most honest reading is that amoxicillin alone is the guideline-recommended first choice, the benefit over placebo is modest, and the studies claiming superiority for other drugs are too small or too conflicted to trust.
My call: for a patient who meets the criteria for bacterial sinusitis, amoxicillin is the guideline-supported choice, but the absolute benefit is modest and the evidence for any alternative is weak. Confidence: moderate that amoxicillin is appropriate first-line; low that any alternative is better.
Sources used 8
-
The inhalation antibioticotherapy of acute bacterial rhinosinusitis
In an open randomized parallel-group trial, 60 adults with moderate acute bacterial rhinosinusitis receiving either topical pulsed inhalation with thiamphenicol glycinate N-acetylcysteinate via Pari Sinus or oral amoxicillin/clavulanate both showed significant symptom improvemen…
DOI: 10.21518/2079-701x-2018-20-50-54 -
Evaluation of the clinical efficacy of local antibacterial therapy in the treatment of acute bacterial rhinosinusitis
In 100 patients with moderate acute bacterial rhinosinusitis, adding Polydexa with phenylephrine nasal spray to systemic amoxicillin/clavulanate versus control (oxymetazoline) accelerated improvement of subjective symptoms, rhinoscopic edema/discharge resolution, and radiographi…
DOI: 10.26442/00403660.2020.12.000834 -
EFFICACY OF A CO₂-ENRICHED EFFERVESCENT NASAL SPRAY FOR IRRIGATING-ELIMINATIVE THERAPY IN ACUTE BACTERIAL RHINOSINUSITIS
In adults with acute bacterial rhinosinusitis, adjunct nasal irrigation with a CO2-enriched isotonic solution ('Sparklin') reduced symptom severity and normalized nasal mucosal pH significantly more than standard isotonic saline over 14 days.
DOI: 10.37219/wayhev49 -
The use of roxithromycin in the treatment of acute bacterial rhinosinusitis
This narrative review concludes that roxithromycin (Esparoxy) is clinically and bacteriologically effective, well tolerated, and should be widely used in the treatment of acute bacterial rhinosinusitis.
DOI: 10.21518/2079-701x-2018-21-61-65 -
Diagnosis and treatment of uncomplicated acute bacterial rhinosinusitis: Summary of the Agency for Health Care Policy and Research evidence‐based report
This study critically examines the diagnostic tests and treatment efficacy for uncomplicated acute bacterial rhinosinusitis (ABR), concluding that clinical criteria-based treatment with amoxicillin or folate inhibitors is the most cost-effective strategy.
DOI: 10.1016/s0194-5998(00)70135-5 -
Efficacy/safety of amoxicillin/clavulanate in adults with bacterial rhinosinusitis
This study evaluates the efficacy and safety of a pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125 mg) in treating adults with acute bacterial rhinosinusitis, demonstrating high rates of bacteriologic and clinical success, particularly against resist…
DOI: 10.1016/j.amjoto.2005.11.015 -
Pharmacokinetically Enhanced Amoxicillin/Clavulanate (2,000/125 mg) in Acute Bacterial Rhinosinusitis caused by Streptococcus Pneumoniae , Including Penicillin-Resistant Strains
A pooled efficacy analysis of two multinational, nonrandomized trials shows that a pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) given as two 1000/62.5 mg tablets twice daily is highly effective for treating acute bacterial rhinosinusitis caused by Streptoco…
DOI: 10.1177/014556130608500812 -
Principles of appropriate antibiotic use for acute rhinosinusitis in adults: Background
A CDC-published guideline outlining judicious antibiotic use for acute rhinosinusitis in adults, emphasizing that most cases are viral, outlining diagnostic criteria to identify bacterial infection (typically ≥7 days with unilateral facial pain and purulent discharge), recommend…
DOI: 10.1067/s0196-0644(01)70089-3